

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Potlapally, et al.

Serial No. 10/507,399

Filed: April 8, 2005

Confirmation No. 3144

Examiner: T. Truong

Art Unit: 1624

For: **NOVEL CRYSTALLINE FORM OF 5-[4-[[3-METHYL-4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL]METHOXY]BENZYL]THIAZOLIDINE-2,4-DIONE POTASSIUM SALT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

RCE AND RESPONSE

Applicants request continued examination pursuant to 37 CFR 1.114. Please consider this response to the Office Action mailed 27 August 2009 the required submission. The Office is authorized to charge \$1910 for the three-month extension and the RCE fee to Deposit Account 501923. If any additional fees for the accompanying response are required, the Commissioner is authorized to charge those fees to Deposit Account 501923.

Amendments to the claims begin on page 2 of this response.

Remarks begin on page 5 of this response.